Neuropsychiatric symptoms in dementia: Importance and treatment considerations

References

• Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. Journal of Neuropsychiatry & Clinical Neuroscience 2001; 13: 374–379
   PubMedGoogle Scholar
• Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry 2001; 16: 184–191
   PubMed Web of Science ®Google Scholar
• Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias. Journal of Clinical Psychiatry 2005; 66: 633–637
   PubMed Web of Science ®Google Scholar
• Allen-Burge R, Stevens AB, Burgio LD. Effective behavioral interventions for decreasing dementia-related challenging behavior in nursing homes. International Journal of Geriatric Psychiatry 1999; 14: 213–228
   PubMed Web of Science ®Google Scholar
• Alzheimer's Society. Dementia UK: A report to the Alzheimer's Society. Alzheimer's Society, London 2007
   Google Scholar
• Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Archives of Neurology 2004; 61: 1249–1253
   PubMedGoogle Scholar
• Bains J, Birks JS, Dening TD. Antidepressants for treating depression in dementia. Cochrane Dementia and Cognitive Improvement Group Cochrane Database of Systematic Reviews 2007; 3
   Google Scholar
• Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998; 351: 1032–1033
   PubMed Web of Science ®Google Scholar
• Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology 2000; 48: 868–876
   PubMed Web of Science ®Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. British Medical Journal 2005; 330: 874
   PubMed Web of Science ®Google Scholar
• Ballard C, Howard R. Neuroleptic drugs in dementia: Benefits and harm. Nature Reviews Neuroscience 2006; 7: 492–500
   PubMed Web of Science ®Google Scholar
• Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 1
   Google Scholar
• Ballard C, Ayre G, Gray A. Psychotic symptoms and behavioural disturbances in dementia: A review. Revue Neurologique 1999; 155(4)44–52
   Google Scholar
• Ballard C, O'Brien J, James I, Mynt P, Lana M, Potkins D, et al. Quality of life for people with dementia living in residential and nursing home care: The impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. International Psychogeriatrics 2001; 13: 93–106
   PubMed Web of Science ®Google Scholar
• Ballard CG, Margallo-Lana ML. The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. Journal of Clinical Psychiatry 2004; 65(11)23–28
   Google Scholar
• Ballard CG, Eastwood C, Gahir M, Wilcock G. A follow up study of depression in the carers of dementia sufferers. British Medical Journal 1996; 312: 947
   PubMed Web of Science ®Google Scholar
• Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. Journal of Clinical Psychiatry 1995; 62: 631–636
   Google Scholar
• Ballard CG, O’Brien J, Reichelt K, Perry E. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind, placebo-controlled trial with Melissa. Journal of Clinical Psychiatry 2002; 63: 553–558
   PubMed Web of Science ®Google Scholar
• Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cut-off is a predictor of clinical outcome. Journal of Clinical Psychiatry 2004; 65: 114–119
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database of Systematic Reviews 2007; 3
   Google Scholar
• Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database of Systematic Reviews 2007; 3
   Google Scholar
• Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a double-blind baseline-treatment-controlled pilot study. Journal of Geriatric Psychiatric Neurology 1997; 10: 119–126
   PubMed Web of Science ®Google Scholar
• Burns A, Byrne J, Ballard C, Holmes C. Sensory stimulation in dementia. British Medical Journal 2002; 325: 1312–1313
   PubMed Web of Science ®Google Scholar
• Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood. British Journal of Psychiatry 1990; 157: 92–94
   Web of Science ®Google Scholar
• Burns A, Lewis G, Jacoby R, Levy R. Factors affecting survival in Alzheimer's disease. Psychological Medicine 1991; 21: 363–370
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: A controlled trial of systematic individualized intervention. Journals of Gerontology Series A-Biological Sciences & Medical Sciences 2007; 62: 908–916
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: A controlled, double-blind study. Archives of Internal Medicine 1999; 159: 1733–1740
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. Journal of Gerontolology A Biological Sciences Medical Sciences 1997; 52: 3690–3697
   Google Scholar
• CSM. Atypical antipsychotic drugs and stroke. Committee on Safety of Medicines (CSM) 9-3-2004, 2004
   Google Scholar
• Cummings JL, Schneider E, Tariot PN, Graham SM. Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67: 57–63
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004; 351: 2509–2518
   PubMed Web of Science ®Google Scholar
• Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Archives of General Psychiatry 2000; 57: 1165–1173
   PubMed Web of Science ®Google Scholar
• FDA. Deaths with antipsychotics in elderly patients with behavioral disturbances. U.S. Food and Drug Health Advisory, Centre for Drug Evaluation and Research, Washington, DC 2005; 13–17, Available at http://www.fda.gov/Cder/drug/advisory
   Google Scholar
• Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. British Journal of Psychiatry 1993; 163: 364–368
   Google Scholar
• Forstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychological Medicine 1992; 22: 877–884
   PubMed Web of Science ®Google Scholar
• Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial. British Medical Journal 2006; 332: 756–761
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics 2002; 14: 389–404, Donepezil MSAD Study Investigators Group
   PubMed Web of Science ®Google Scholar
• Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in Alzheimer's disease. Journal of Neuropsychiatry & Clinical Neuroscience 1991; 3: 371–376
   PubMed Web of Science ®Google Scholar
• Greenwald BS, Kramer-Ginsberg E, Marin DB, Laitman LB, Hermann CK, Mohs RC, et al. Dementia with coexistent major depression. American Journal of Psychiatry 1989; 146: 1472–1478
   PubMed Web of Science ®Google Scholar
• Haupt M, Kurz A, Janner MA. Two-year follow-up of behavioral and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 147–152
   PubMed Web of Science ®Google Scholar
• Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer's disease: The effect of dopamine receptor gene variation. Journal of Neurology, Neurosurgery & Psychiatry 2001; 71: 777–779
   PubMed Web of Science ®Google Scholar
• Hoogendijk WJ, Sommer IE, Pool CW, Kamphorst W, Hofman MA, Eikelenboom P, et al. Lack of association between depression and loss of neurons in the locus coeruleus in Alzheimer disease. Archives of General Psychiatry 1999; 56: 45–51
   Google Scholar
• Howard R, Ballard C, O'Brien J, Burns A. UK and Ireland Group for Optimization of Management in dementia. Guidelines for the management of agitation in dementia. International Journal of Geriatric Psychiatry 2001; 16: 714–717
   PubMedGoogle Scholar
• Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine 2007; 357: 1382–1392, CALM-AD Trial Group.
   PubMed Web of Science ®Google Scholar
• Klatka L, Louis E, Schiffer RB. Psychiatric features in diffuse Lewy body disease; A linicopathologic study using Alzheimer's disease and Parkinson's disease control groups. Neurology 1996; 47: 1148–1152
   PubMed Web of Science ®Google Scholar
• Kurlan R, Cummings J, Raman R, Thal L. Alzheimers disease cooperative study group. Quetapine for in Patients with dimentia and Partinsors. Neurology 2007; 68: 1356–1363
   PubMed Web of Science ®Google Scholar
• Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. American Journal of Psychiatry 2005; 62: 1996–2021
   Google Scholar
• Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database of Systematic Reviews 2007; 4
   Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database of Systematic Reviews 2007; 3
   Google Scholar
• Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry 2003; 60: 737–746
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry 2000; 157: 708–714
   PubMed Web of Science ®Google Scholar
• Margallo-Lana M, Swann A, O'Brien J, Fairbairn A, Reichelt K, Potkins D, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. International Journal of Geriatric Psychiatry 2001; 16: 39–44
   PubMed Web of Science ®Google Scholar
• Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, et al. Noncognitive disturbances in Alzheimer's disease: Frequency, longitudinal course, and relationship to cognitive symptoms. Journal of the American Geriatrics Society 1997; 45: 1331–1338
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–2036
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 65: 1863–1872
   PubMed Web of Science ®Google Scholar
• McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal 1992; 305: 673–678
   PubMed Web of Science ®Google Scholar
• McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. British Medical Journal 1997; 314: 266–270
   PubMed Web of Science ®Google Scholar
• Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460–1467
   PubMed Web of Science ®Google Scholar
• Moniz-Cook E, Woods RT, Richards K. Functional analysis of challenging behaviour in dementia: The role of superstition. International Journal of Geriatric Psychiatry 2001; 16: 45–56
   PubMed Web of Science ®Google Scholar
• National Audit Office. Improving services and support for people with dementia. National Audit Office, Washington, DC 2007
   Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G. Behavioral alterations and vascular dementia. Neurologist 2006; 12: 43–47
   PubMed Web of Science ®Google Scholar
• Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. British Journal of Psychiatry 1990; 157: 894–901
   PubMed Web of Science ®Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Dementia and Cognitive Improvement Group. Cochrane Database of Systematic Reviews 2003; 3
   Google Scholar
• Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Journal of Neuropsychiatry & Clinical Neurosciences 1996; 8: 270–275
   PubMed Web of Science ®Google Scholar
• Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics 2001; 13: 233–40
   PubMed Web of Science ®Google Scholar
• Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. Journal of Neurochemistry 1990; 55: 1454–1456
   PubMed Web of Science ®Google Scholar
• Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: Comparisons with Parkinson's disease. Biological Psychiatry 1998; 44: 765–774
   Google Scholar
• Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psychiatry 2007; 15: 942–952
   PubMed Web of Science ®Google Scholar
• Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. Journal of the American Medical Society 1982; 248: 333–335
   PubMed Web of Science ®Google Scholar
• Reifler BV, Teri L, Reskind M, Veith R, White E, McLeen P. Doubleldind trial of imipramine in Alzheimers disease patients with and without depression. American Journal of Psychiatry 1989; 146: 45–49
   PubMed Web of Science ®Google Scholar
• Rovner BW, Steele CD, Shmuely Y, Folstein MF. A randomized trial of dementia care in nursing homes. Journal of the American Geriatrics Society 1996; 44: 7–13
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 2006; 14: 191–210
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005; 294: 1934–1943
   PubMed Web of Science ®Google Scholar
• Sharp SI, Ballard CG, Chen CP, Francis PT. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. American Journal of Geriatric Psychiatry 2007; 15: 435–437
   PubMed Web of Science ®Google Scholar
• Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 1990; 147: 1049–1051
   PubMed Web of Science ®Google Scholar
• Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Archives of Neurology 1998; 55: 1335–1340
   PubMedGoogle Scholar
• Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. International Psychogeriatrics 2001; 13: 401–409
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. American Journal of Geriatric Psychiatry 1997; 5: 60–69
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. American Journal of Psychiatry 1993; 150: 1806–1812
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Archives of Neurology 1996; 53: 175–179
   PubMed Web of Science ®Google Scholar
• Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry 1998; 155: 54–61
   PubMed Web of Science ®Google Scholar
• Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: A randomized controlled trial. Journal of the American Medical Association 2003; 290: 2015–2022
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Alzheimer's Disease Cooperative Study. Neurology 2000; 55: 1271–1278
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: A controlled clinical trial. Journal of Gerontol B Psychol Sci Soc Sci 1997; 52: 159–166
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease. Journal of Clinical Psychiatry 2008; 69: 341–348
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Archives of Neurology 1992; 48: 619–624
   Google Scholar